Welcome to our dedicated page for Arcadia Bioscien news (Ticker: RKDA), a resource for investors and traders seeking the latest updates and insights on Arcadia Bioscien stock.
Arcadia Biosciences, Inc. reports developments tied to its plant-based health and wellness products business, including Zola coconut water and agronomic wheat traits. Company news includes operating and financial results, business highlights, material agreements, shareholder voting matters, and capital-structure actions involving its publicly traded common stock.
Recurring updates also cover governance matters, security-structure disclosures, and other corporate events that affect the company's financing, reporting, and operating profile.
Arcadia Biosciences (RKDA) announced the sale of its non-GMO Resistant Starch (RS) Durum Wheat trait to Corteva Agriscience for $4 million. This transaction involves the transfer of 24 patents across 20 countries. Arcadia retains the right to continue using the RS Durum Wheat trait in its GoodWheat product line. The sale aims to monetize Arcadia's wheat technology and strengthen its balance sheet, facilitating future strategic transactions. Corteva and Arcadia's collaboration since 2017 has focused on developing and commercializing RS Durum, a wheat variant with up to 94% amylose, offering health benefits like improved gut health and a lower glycemic index.
Arcadia Biosciences (RKDA) reported positive financial results and business highlights for the first quarter of 2024, with revenue growth both sequentially and year-over-year. The company achieved its lowest loss from continuing operations in six years, showcasing a positive trend in revenue generation and gross profit margins. Operating expenses declined, and the company continued to expand its product reach and distribution, focusing on high-quality revenue sources. Key highlights include the expansion of GoodWheat and Zola products in multiple stores, driving revenue and gross profit growth. Overall, Arcadia Biosciences remains on a positive trajectory with a strong focus on monetizing its IP and delivering cashflow positive results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.